What is the 13F Pro Quality Score for TRDA?

13F Pro ranks Entrada Therapeutics, Inc. (TRDA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TRDA's current score at https://13fpro.ai/company/TRDA (free sign-up required for the full ranking).

Which hedge funds own the most TRDA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TRDA include BAKER BROS. ADVISORS, 5AM Venture Management,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TRDA as soon as new 13F filings post.

Where does 13F Pro source TRDA data?

All Entrada Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Entrada Therapeutics, Inc. files with the SEC under CIK 1689375. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TRDA in?

Entrada Therapeutics, Inc. (TRDA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TRDA research updated on 13F Pro?

TRDA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Entrada Therapeutics, Inc.(TRDA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1689375 TRDA stock profile & AI dashboard →

13F Pro Quality Score

7.3/100

Rank #2,948 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

0.3/100

Profitability

1.2/100

Balance Sheet

4.3/100

Earnings Quality

20.4/100

Free Cash Flow

1.0/100

Institutional Flow

77.3/100

Revenue Scale

1.3/100

Dilution Risk

3.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TRDA Scores 7/100

exact factor attribution · 2026-09-11

TRDA's composite is driven by institutional flow, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+1.4 pts

77th pct

Earnings growth

-2.3 pts

4th pct

Shareholder dilution

-2.3 pts

4th pct

Earnings quality

-3.0 pts

20th pct

Capital efficiency

-4.6 pts

4th pct

Scale

-7.3 pts

1th pct

Profitability

-7.3 pts

1th pct

Free cash flow

-7.3 pts

1th pct

Revenue growth

-9.9 pts

0th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TRDA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Entrada Therapeutics, Inc. (TRDA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TRDA at 7.3/100 on a 32-signal composite quality model, placing it at rank #2,948 of 2,962 stocks — the bottom half of the AI-ranked universe. TRDA scores in the top quartile across institutional flow (77.3). Areas of concern include revenue growth (0.3) and free cash flow (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Entrada Therapeutics, Inc. reports quarterly revenue of $898.0K, net income of $-42.8M, free cash flow of $-32.5M. Top institutional holders of TRDA by reported 13-F value include BAKER BROS. ADVISORS, 5AM Venture Management, BlackRock, based on the most recent SEC filings. TRDA trades on the Nasdaq exchange and files with the SEC under CIK 1689375. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Entrada Therapeutics, Inc. directly from SEC EDGAR. Entrada Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 65 since 2024, currently 7.3 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q2 2026

$898.0K

Net Income

Q2 2026

$-42.8M

Free Cash Flow

Q2 2026

$-32.5M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-87.9% YoY

$25.4MFY 2025

FY22 —FY23 $129.0MFY24 $210.8MFY25 $25.4M

Net Income

-319.0% YoY

$-143.8MFY 2025

FY22 $-94.6MFY23 $-6.7MFY24 $65.6MFY25 $-143.8M

Operating Income

-435.9% YoY

$-157.9MFY 2025

FY22 $-97.2MFY23 $-3.2MFY24 $47.0MFY25 $-157.9M

EPS (Diluted)

-306.5% YoY

$-3.47FY 2025

FY22 $-3.02FY23 $-0.20FY24 $1.68FY25 $-3.47

Total Assets

-28.3% YoY

$377.4MFY 2025

FY22 $252.1MFY23 $469.2MFY24 $526.3MFY25 $377.4M

Op. Cash Flow

-209.2% YoY

$-128.5MFY 2025

FY22 $-93.8MFY23 $139.8MFY24 $-41.6MFY25 $-128.5M

Free Cash Flow

-189.7% YoY

$-129.6MFY 2025

FY22 $-96.7MFY23 $134.2MFY24 $-44.7MFY25 $-129.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$25.4M -87.9%	$210.8M +63.4%	$129.0M	—	—	—
Net Income	$-143.8M -319.0%	$65.6M +1081.7%	$-6.7M +92.9%	$-94.6M -84.9%	$-51.2M -92.9%	$-26.5M
Operating Income	$-157.9M -435.9%	$47.0M +1586.7%	$-3.2M +96.7%	$-97.2M -90.2%	$-51.1M -91.7%	$-26.7M
EPS (Diluted)	$-3.47 -306.5%	$1.68 +940.0%	$-0.20 +93.4%	$-3.02 +63.0%	$-8.16 +66.0%	$-24.00
Total Assets	$377.4M -28.3%	$526.3M +12.2%	$469.2M +86.1%	$252.1M -17.6%	$305.8M +602.6%	$43.5M
Operating Cash Flow	$-128.5M -209.2%	$-41.6M -129.7%	$139.8M +249.1%	$-93.8M -84.4%	$-50.9M -98.9%	$-25.6M
Free Cash Flow	$-129.6M -189.7%	$-44.7M -133.3%	$134.2M +238.8%	$-96.7M -74.4%	$-55.4M -98.8%	$-27.9M

Get alerted when TRDA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Entrada Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TRDA

BAKER BROS. ADVISORS LP
$37.3M5,072,730 sh
5AM Venture Management, LLC
$29.9M4,056,379 sh
BlackRock, Inc.
$19.0M2,583,333 sh
Merck & Co., Inc.
$12.8M1,739,768 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.3M1,269,634 sh
MPM BioImpact LLC
$9.2M1,253,053 sh
TCG Crossover Management, LLC
$7.8M1,060,230 sh
WELLINGTON MANAGEMENT GROUP LLP
$7.0M954,419 sh
MILLENNIUM MANAGEMENT LLC
$5.6M763,959 sh
StepStone Group LP
$5.6M761,277 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$37.3M	5,072,730
5AM Venture Management, LLC	$29.9M	4,056,379
BlackRock, Inc.	$19.0M	2,583,333
Merck & Co., Inc.	$12.8M	1,739,768
VANGUARD CAPITAL MANAGEMENT LLC	$9.3M	1,269,634
MPM BioImpact LLC	$9.2M	1,253,053
TCG Crossover Management, LLC	$7.8M	1,060,230
WELLINGTON MANAGEMENT GROUP LLP	$7.0M	954,419
MILLENNIUM MANAGEMENT LLC	$5.6M	763,959
StepStone Group LP	$5.6M	761,277

Companies Similar to TRDA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SLN

Silence Therapeutics plc

AI score

Very similar · 7 shared holders

TCG Crossover Management, LLC 5AM Venture Management, LLC Nantahala Capital Management, LLC

ALEC

Alector, Inc.

AI score

Very similar · 8 shared holders

TCG Crossover Management, LLC Merck & Co., Inc.JACOBS LEVY EQUITY MANAGEMENT, INC

GLUE

Monte Rosa Therapeutics, Inc.

AI score

Very similar · 8 shared holders

BAKER BROS. ADVISORS LP MPM BioImpact LLC TCG Crossover Management, LLC

XNCR

Xencor Inc

AI score

Very similar · 7 shared holders

BAKER BROS. ADVISORS LP TCG Crossover Management, LLC Susquehanna Portfolio Strategies, LLC

ALMS

ALUMIS INC.

AI score

Similar quality profile · 10 shared holders

BAKER BROS. ADVISORS LP MPM BioImpact LLC MOORE CAPITAL MANAGEMENT, LP

ACRS

Aclaris Therapeutics, Inc.

AI score

Similar quality profile · 6 shared holders

MPM BioImpact LLC Susquehanna Portfolio Strategies, LLC Verdad Advisers, LP

CLDX

Celldex Therapeutics, Inc.

AI score

Similar quality profile · 6 shared holders

BAKER BROS. ADVISORS LP 5AM Venture Management, LLC Susquehanna Portfolio Strategies, LLC

STRO

SUTRO BIOPHARMA, INC.

AI score

Similar quality profile · 3 shared holders

Merck & Co., Inc.Verdad Advisers, LP ADAR1 Capital Management, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TRDA on your watchlist

Track score changes the day Entrada Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TRDA a good stock to buy?

13F Pro's AI-powered analysis of Entrada Therapeutics, Inc. (TRDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRDA are available on the TRDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TRDA is classified as a small company.

Which hedge funds own TRDA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Entrada Therapeutics, Inc.'s investment landscape.